Avecho Biotechnology Records positive results from Phase IIa osteoarthritis study
- Avecho Biotechnology (AVE) sees positive results from its Phase IIa Study of its CBD formulation on patients with osteoarthritis (OA)
- The study investigated the effects of a topical CBD gel on OA of the hand with 15 patients recruited to apply Avecho’s TPM formulation daily to the affected joints
- The primary aim of the study was to measure the change in daily hand pain while the secondary aim included improving hand functionality
- Over the four weeks, daily improvements were encountered in hand pain, hand functionality, grip strength, stiffness and anxiety
- Avecho is up 7.69 per cent on the market with shares trading at 1.4 cents
